The ophthalmology drugs market covers drugs that are used in the treatment of eye related diseases such as refractive errors, cataracts, glaucoma, conjunctivitis, retinal diseases, and macular degeneration. Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax.
North America was the largest region in the ophthalmology drugs market in 2017, accounting for around 30% market share. This was mainly due to the high per capita healthcare expenditure and access to advanced eye care facilities in the region. Western Europe was the second largest region accounting for around 22% market share. Africa was the smallest region accounting for around 3% market share.
Rho-Kinase Inhibitors in Glaucoma Treatment - Drug manufacturers are developing new class of compounds called Rho-kinase inhibitors for the treatment of glaucoma. Rho-kinase pathway is an integral part of cellular functions such as contraction of vascular smooth muscle cells, organization of the actin cytoskeleton, cell adhesion and motility and gene expression.
These inhibitors are different from widely used prostaglandin analogs because they target the outflow through trabecular meshwork rather than the uveoscleral outflow. Rho-kinase inhibitors have proved to decrease intraocular pressure by 25% to 30% with duration of action of 10 to 12 hours, which is more effective than the previous generation of drugs for this condition. Major Rho-kinase inhibitors being developed include ATS907, ATS8535, AR-12286, AR-13324, AMA0076 and BOL-303259-X.
- Markets Covered: Antiglaucoma Drugs, Dry Eye Medication, and other Ophthalmological Drugs.
- Time Series: Five years historic and forecast.
- Data: Market value in $ billions.
- Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Allergan Plc.
- Valeant Pharmaceuticals Intl Inc.
- Bayer AG
- Santen Pharmaceutical Co. Ltd.
- Otsuka Pharmaceutical Co. Ltd.
- Shire Plc
For more information about this report visit https://www.researchandmarkets.com/research/d46n78/global?w=4